ATE243252T1 - Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie - Google Patents

Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie

Info

Publication number
ATE243252T1
ATE243252T1 AT00920847T AT00920847T ATE243252T1 AT E243252 T1 ATE243252 T1 AT E243252T1 AT 00920847 T AT00920847 T AT 00920847T AT 00920847 T AT00920847 T AT 00920847T AT E243252 T1 ATE243252 T1 AT E243252T1
Authority
AT
Austria
Prior art keywords
pim
pharmaceutical composition
therapy
composition containing
nkt cells
Prior art date
Application number
AT00920847T
Other languages
English (en)
Inventor
Irina Apostolov
Gabriel Gachelin
Philippe Kourilsky
Yousuke Takahama
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE243252T1 publication Critical patent/ATE243252T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00920847T 1999-04-19 2000-04-19 Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie ATE243252T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904897A FR2792205B1 (fr) 1999-04-19 1999-04-19 Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
PCT/FR2000/001029 WO2000063348A2 (fr) 1999-04-19 2000-04-19 Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie

Publications (1)

Publication Number Publication Date
ATE243252T1 true ATE243252T1 (de) 2003-07-15

Family

ID=9544579

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920847T ATE243252T1 (de) 1999-04-19 2000-04-19 Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie

Country Status (12)

Country Link
US (2) US7052909B1 (de)
EP (2) EP1346725A1 (de)
JP (1) JP2003502284A (de)
AT (1) ATE243252T1 (de)
CA (1) CA2368029A1 (de)
DE (1) DE60003417T2 (de)
DK (1) DK1171578T3 (de)
ES (1) ES2206221T3 (de)
FR (1) FR2792205B1 (de)
HK (1) HK1044795B (de)
PT (1) PT1171578E (de)
WO (1) WO2000063348A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505538A (en) * 2000-07-03 2004-12-24 Malaghan Inst Of Medical Res A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
FR2815641B1 (fr) * 2000-10-24 2002-12-27 Pasteur Institut Procede de criblage de molecules actives dans la prevention et le traitement des lesions atherosclereuses et ses applications
SI1537204T1 (sl) * 2002-08-23 2010-06-30 Gabriele Prof Dr Multhoff Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
WO2006009731A1 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Methods of using apo2l receptor agonists and nk cell activators
FR2908658B1 (fr) * 2006-11-20 2011-11-11 Centre Nat Rech Scient Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE286735T1 (de) * 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
JP2001515868A (ja) * 1997-09-12 2001-09-25 ブライハム アンド ウイメンズ ホスピタル Ｃｄ１制限免疫応答のための合成抗原
CA2323733A1 (en) * 1998-04-13 1999-10-21 Michael B. Brenner Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof

Also Published As

Publication number Publication date
CA2368029A1 (fr) 2000-10-26
FR2792205A1 (fr) 2000-10-20
EP1171578B1 (de) 2003-06-18
DE60003417T2 (de) 2004-05-06
EP1171578A2 (de) 2002-01-16
ES2206221T3 (es) 2004-05-16
FR2792205B1 (fr) 2001-07-27
US7052909B1 (en) 2006-05-30
WO2000063348A3 (fr) 2000-12-28
DE60003417D1 (de) 2003-07-24
PT1171578E (pt) 2003-11-28
JP2003502284A (ja) 2003-01-21
HK1044795B (zh) 2003-10-10
EP1346725A1 (de) 2003-09-24
US20060263376A1 (en) 2006-11-23
WO2000063348A2 (fr) 2000-10-26
HK1044795A1 (en) 2002-11-01
DK1171578T3 (da) 2003-10-13

Similar Documents

Publication Publication Date Title
CO5570656A2 (es) Liberacin controlada de una sustancia activa a un entorno rico en grasa
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE344801T1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
KR20150008858A (ko) 생체 광자성 조성물들, 키트들 및 방법들
ATE460199T1 (de) Medizinische vorrichtung zur verabreichung von therapeutischem gas
EP2305276A3 (de) Zellen aus Lipoaspirat und ihre Verwendung zur Therapie
ATE456954T1 (de) Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren
ATE243252T1 (de) Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie
ATE421319T1 (de) Mit s-nitrosothiol angereicherte erythrocyten und deren verwendung
ATE513555T1 (de) Pharmazeutische kombination aus g-csf und plgf für blutstammzellen
FI972004A0 (fi) Implantoitava laite vaikuttavien aineiden antamiseen kasveille
FI962550A0 (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
EP3710108A1 (de) Modulation von biophotonischen dosierplänen
Anitua et al. A novel autologous topical serum based on plasma rich in growth factors technology counteracts ultraviolet light-derived photo-oxidative stress
DE69528473D1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
SHIRAI et al. Difference in Cell Viability between with and without Visible Light-irradiation by Camphorquinone (CQ)-containing Medium
Hong et al. Assessment of superoxide-mediated release of vascular-inhibitory factor (s) from endothelial cells by using a two-bath system
Iwamoto et al. Phenformin stimulation of insulin binding to human cultured lymphocytes
Lara et al. understanding the role of adipocytes and the tumor microenvironment on doxorubicin therapy of breast cancer in a tissue engineered, patient specific, high-throughput biomimetic platform
DE69008282D1 (de) Kaffeesäure-Derivate, deren Verwendung für medizinische Behandlungen und diese enthaltende pharmazeutische Zusammensetzungen.
TR200100020T2 (tr) Gliserol trinitrat içerikli bileşim, imalat yöntemleri ve kullanımı
ATE319410T1 (de) Verfahren zur kosmetischen behandlung von keratinischen materialen, wobei aromatische wirkstoffe aus aromatischen polymerpartikeln kontrolliert freigesetzt werden
DE50305753D1 (de) Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1171578

Country of ref document: EP

REN Ceased due to non-payment of the annual fee